BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Adhoute X, Penaranda G, Raoul JL, Sellier F, Castellani P, Oules V, Perrier H, Lefolgoc G, Pol B, Campanile M. Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study. Eur J Gastroenterol Hepatol. 2018;30:368-375. [PMID: 29384796 DOI: 10.1097/meg.0000000000001082] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Guarino M, Sessa A, Cossiga V, Morando F, Caporaso N, Morisco F, On behalf of the Special Interest Group on “Hepatocellular carcinoma and new anti-HCV therapies” of the Italian Association for the Study of the Liver. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows. World J Gastroenterol 2018; 24(24): 2582-2595 [PMID: 29962815 DOI: 10.3748/wjg.v24.i24.2582] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
2 Sanduzzi-Zamparelli M, Boix L, Leal C, Reig M. Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents. Viruses 2019;11:E406. [PMID: 31052463 DOI: 10.3390/v11050406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
3 El Kassas M, Tawheed A, Eltabbakh M, Kaseb A. Hepatitis C Antiviral Therapy In Patients With Successfully Treated Hepatocellular Carcinoma: Dancing With Wolves. J Hepatocell Carcinoma 2019;6:183-91. [PMID: 31819865 DOI: 10.2147/JHC.S206668] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Gao X, Zhan M, Wang L, Ding Y, Niu J. Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC. J Hepatocell Carcinoma 2020;7:347-60. [PMID: 33299823 DOI: 10.2147/JHC.S279657] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
5 Pradat P, Virlogeux V, Trépo E. Epidemiology and Elimination of HCV-Related Liver Disease. Viruses 2018;10:E545. [PMID: 30301201 DOI: 10.3390/v10100545] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
6 Khaliq S, Raza SM. Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan. Medicina (Kaunas) 2018;54:E80. [PMID: 30400604 DOI: 10.3390/medicina54050080] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
7 Zanaga LP, Santos AG, Ataíde EC, Boin IFSF, Stucchi RSB. Recurrent hepatitis C treatment with direct acting antivirals - a real life study at a Brazilian liver transplant center. Braz J Med Biol Res 2019;52:e8519. [PMID: 31389490 DOI: 10.1590/1414-431X20198519] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Tampaki M, Savvanis S, Koskinas J. Impact of direct-acting antiviral agents on the development of hepatocellular carcinoma: evidence and pathophysiological issues. Ann Gastroenterol 2018;31:670-9. [PMID: 30386116 DOI: 10.20524/aog.2018.0306] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
9 Adhoute X, Castellani P, Bourlière M. Impact of direct-acting antiviral agents on the risk for hepatocellular carcinoma. Transl Gastroenterol Hepatol 2017;2:110. [PMID: 29354767 DOI: 10.21037/tgh.2017.12.04] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]